New TIL therapy improves treatment’s effectiveness in patients with metastatic gastrointestinal cancers

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH).

Leave a Reply